Germany’s NOXXON in “significant” collaboration with Eli Lilly
NOXXON Pharma AG has signed a licensing and drug discovery agreement with Eli Lilly of the US, its third such deal with a multinational pharmaceutical company in a little over two years.
News
Pharming reports on North American Rhucin trial
Pharming Group NV said that the results of its Phase 3 North American trial of the recombinant human protein, Rhucin, were positive enabling it to proceed with regulatory filings in both the US and Europe.
Novartis withdraws application for pre-pandemic vaccine
Novartis Vaccines and Diagnostics, a unit of Novartis, has told the European Medicines Agency (EMEA) that it is withdrawing its marketing authorisation application for Aflunov, a pre-pandemic vaccine.
Germany’s SYGNIS gets access to US CNS technology via acquisition
SYGNIS Pharma AG is acquiring the closely-held US biopharmaceutical company, Amnestix Inc, for €4 million, paying a combination of cash and shares.
Genmab expects 2008 revenues of 1 billion Danish Krone
Genmab A/S, which develops therapies based on fully human antibodies, expects to report revenue of 1 billion Danish Krone (DKK) in 2008. However, it is projecting an operating loss of DKK 900 to 1,000 million and a net loss in the range of DKK 800 to 900 million.
Jerini expects launch of Icatibant in third 2008 quarter
Jerini AG expects to launch its treatment for acute attacks of hereditary angioedema (HAE), Icatibant, in Europe in the third quarter of 2008 following a positive opinion from the main scientific committee of the European Medicine Agency in April. The company expects to receive a marketing authorisation from the European Commission in late June or early July, a spokeswoman told MedNous.
Ablynx gives business update
Ablynx NV of Ghent, Belgium, which is developing a new class of antibody-derived therapeutic proteins called Nanobodies, said that revenues for the first quarter of 2008 were €3.3 million, up by 53% compared with €2.1 million a year earlier.
Protherics says revenue grew 27% in fiscal year
Protherics Plc, which focuses on specialist products for critical care and cancer, reported trading revenues of £23.5 million for the year ended 31 March 2008, up by 27% from the previous period.
The EMEA briefs journalists on the changing regulatory paradigm
There has been a gradual, but fundamental shift in the way regulatory agencies interact with the pharmaceutical industry, so that it is now commonplace for companies to meet with regulators before drug development gets into full swing.
Ipsen strengthens its position in the US with acquisitions
Ipsen SA has announced three separate deals to acquire assets in the US relating to the fields of endocrinology, neuromuscular disorders and haematology.